Gyre Therapeutics Inc SEC Filings

Gyre Therapeutics, Inc. furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 to this Form 8-K.

Consistent with General Instruction B.2, the information in Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act. Gyre’s common stock trades on The Nasdaq Capital Market under the symbol GYRE. The report was signed by Ping Zhang, Executive Chairman and Interim Chief Executive Officer.

Gyre Therapeutics, Inc. filed a Form 8-K reporting that on September 10, 2025 the company made an updated corporate presentation available on its website and filed that presentation as Exhibit 99.1 to the report. The filing notes the exhibit is dated September 2025 and that the report was signed by Ping Zhang, Executive Chairman and Interim Chief Executive Officer. The 8-K does not include financial results, transaction details, or other operational disclosures; it solely documents the availability and filing of the corporate presentation.

Gyre Therapeutics director Dan Weng was granted a stock option on 08/18/2025 to buy 52,000 shares of common stock at an exercise price of $7.85 per share. The option has a 10-year term expiring 08/18/2035 and vests in 36 equal monthly installments through 08/18/2028, subject to continued service. Following the reported transaction the Reporting Person beneficially owns 52,000 option shares on a direct basis. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/26/2025.

Gyre Therapeutics director Dan Weng filed an SEC Form 3 disclosing no beneficial ownership of Gyre Therapeutics, Inc. (GYRE) common stock. The filing, dated 08/18/2025 for the event and signed 08/26/2025 by an attorney-in-fact, lists Weng's San Diego office address and indicates the report was filed by one reporting person. The filing includes Exhibit 24 (Power of Attorney).

Gyre Therapeutics, Inc. appointed Dr. Dan Weng as a Class II director on August 18, 2025. Dr. Weng, age 63, is the President and CEO of Medelis, Inc. and previously led EPS International Holding Co., with extensive senior roles at global contract research organizations and research positions at Harvard Medical School and Massachusetts General Hospital. The company states that GNI Group Ltd., its parent, identified and supports his appointment. Dr. Weng will receive standard non-employee director compensation per the company’s proxy and will enter the company’s standard indemnification agreement. The filing notes there are no family relationships or reportable related-party transactions requiring disclosure.

Gyre Therapeutics (GYRE) reported consolidated revenue of $26.8 million for the quarter and $48.8 million for the six months ended June 30, 2025, driven by Gyre Pharmaceuticals product sales. Net income was $1.58 million for the quarter and $5.31 million for six months; net income attributable to common stockholders was $0.44 million for the quarter and $3.14 million for six months. Cash and cash equivalents increased to $36.5 million on June 30, 2025, aided by a May 2025 underwritten offering that raised $23.0 million gross (net proceeds ~$21.3 million) and ATM proceeds of $0.5 million.

The company launched two products in 2025—Contiva (commercialization began March 2025) and Etorel (commercialization began June 2025); Etorel technology rights were recorded at ~$4.9 million. Total assets were $152.6 million and total equity $129.4 million. Management states existing liquidity and access to capital are expected to fund operations for at least 12 months. Key risks disclosed include heavy customer concentration (Sinopharm ~52% of revenue/accounts receivable), PRC cross-border restrictions and an accumulated deficit of $70.3 million.

Gyre Therapeutics reported a leadership transition and furnished a press release with its quarterly results. Ping Zhang was appointed Interim Chief Executive Officer effective August 5, 2025, succeeding Han Ying, Ph.D., who resigned as CEO and as a director to become the companys Senior Vice President, Science. Mr. Zhang has served as a company director since January 2025 and as Executive Chair since March 2025, and his background includes senior roles in private equity, venture capital and corporate leadership in China and Japan.

In connection with the interim CEO appointment, Mr. Zhang received a grant of 250,000 stock options, with 25% vesting on August 5, 2026 and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The company furnished a press release as Exhibit 99.1 announcing financial results for the three and six months ended June 30, 2025, and listed the interactive data cover page as Exhibit 104.

Gyre Therapeutics director Zhang Ping received a stock option grant to purchase 250,000 shares of the company's common stock with an exercise price of $6.92. The transaction date is 08/05/2025. The option vests 25% on 08/05/2026 and the remainder vests in equal monthly installments over the following three years, contingent on continued service. The option has an expiration date of 08/05/2035 and the reporting form shows 250,000 derivative securities beneficially owned following the grant, held directly.